

Amendment

In the Claims:

Please amend claims 1, 4, 13, 23 and 25-27 as follows:

C1
1. (Amended) A pharmaceutical composition for repair of epithelial tissues comprising a first polypeptide having the biological activity of a platelet derived growth factor (PDGF) and a second polypeptide having the biological activity of keratinocyte growth factor (KGF), wherein the first polypeptide is selected from the group consisting of a full-length PDGF, a biologically active fragment of a full-length PDGF, a biologically active analog of a PDGF comprising at least one amino acid substitution, deletion or addition, and a biologically active derivative of a PDGF, and the second polypeptide is selected from the group consisting of a biologically active fragment of a full-length KGF, a biologically active analog of a KGF comprising at least one amino acid substitution, deletion or addition, and a biologically active derivative of a KGF.

C2
4. (Amended) The pharmaceutical composition of claim 1, wherein the [first polypeptide] PDGF comprises one selected from the group consisting of PDGF A chain and PDGF B chain.

C3
13. (Twice amended) A method of repairing or preventing epithelial cell damage comprising applying to the cells to be protected or repaired PDGF and KGF selected from the group consisting of a biologically active fragment of a full-length KGF, a biologically active analog of a KGF comprising at least one amino acid substitution, deletion or addition, and a biologically active derivative of a KGF,

C3
C4
wherein the PDGF is in a pharmaceutical composition and the KGF is in a pharmaceutical composition.

23. (Twice amended) A kit comprising a [package] container containing the pharmaceutical composition of claim 1 and instructions for use thereof for the prevention of epithelial cell damage and repair of epithelial cells.

C5
25. (Amended) The pharmaceutical composition of claim 1, also comprising a third [polynucleotide] polypeptide having the biological activity of insulin-like growth factor (IGF), wherein the third polypeptide is selected from the group consisting of a full-length IGF, a biologically active fragment of a full-length IGF, a biologically active analog of an IGF comprising at least one amino acid substitution, deletion or addition, and a biologically active derivative of an IGF.

26. (Amended) The pharmaceutical composition of claim 25, wherein the IGF comprises one selected from the group consisting of IGF-1 and IGF-2.

27. (Amended) The pharmaceutical composition of claim 25, also comprising a fourth [polynucleotide] polypeptide having the biological activity of insulin-like growth factor binding protein (IGFBP), wherein the fourth polypeptide is selected from the group consisting of a full-length IGFBP, a biologically active fragment of a full-length IGFBP, a biologically active analog of an IGFBP comprising at least one amino acid substitution, deletion or addition, and a biologically active derivative of an IGFBP.